Achieving early detection and diagnosis of cardiovascular disease: A manifesto for change

Achieving early detection and diagnosis of cardiovascular disease: A manifesto for change

A global, patient-led manifesto, developed collaboratively by 125 international patient advocates, including 40 cardiovascular patient organisations and multidisciplinary expert opinion leaders. 

Early detection and diagnosis of cardiovascular disease can dramatically reduce the burden of illness, improve quality of life for patients and their families, reduce the overall societal burden of chronic disease and substantially enhance population health.

For too long, patients and their families have faced the substantial impact of missed and late detection and diagnosis of cardiovascular disease, which delays treatment initiation and often results in worsened health outcomes.

The manifesto outlines eight actions:

Action 1:
Run public campaigns on the prevalence, causes and symptoms of CVD.
Action 2:
Implement targeted early detection programmes for CVD, at different
stages of life.
Action 3:
Adapt clinical processes to enhance the early detection and diagnosis of CVD.
Action 4:
Leverage digital technologies to increase access to the early detection and diagnosis of CVD.
Action 5:
Optimise workforce training and capacity for the early detection and diagnosis of CVD.
Action 6:
Increase investment in research into the early detection and diagnosis of CVD.
Action 7:
Advance policy development and international partnerships for the early detection and diagnosis of CVD.
Action 8:
Promote equitable access to the early detection and diagnosis of CVD.

A united CVD community is a powerful one. All stakeholders need to come together with a shared commitment to early detection and diagnosis of CVD globally and the time for action is now.

The manifesto outlines eight actions:

Action 1:
Run public campaigns on
the prevalence, causes and symptoms of CVD.
Action 2:
Implement targeted early detection programmes for
CVD, at different stages of life.
Action 3:
Adapt clinical processes to enhance the early detection
and diagnosis of CVD.
Action 4:
Leverage digital
technologies to increase
access to the early detection and
diagnosis of CVD.
Action 5:
Optimise workforce training
and capacity for the early detection and diagnosis of CVD.
Action 6:
Increase investment in
research into the
early detection and diagnosis
of CVD.
Action 7:
Advance policy development
& international partnerships
for the early detection and diagnosis of CVD.
Action 8:
Promote equitable access
to the early detection and
diagnosis of CVD.

A united CVD community is a powerful one. All stakeholders need to come together with a shared commitment to early detection and diagnosis of CVD globally and the time for action is now.

Contributors to the manifesto include:

  • Prof Zanfina Ademi, Head of Health Economics & Policy Evaluation Research (HEPER) group, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia
  • Prof Lina Badimon, Director of Cardiovascular Science Program and Cardiovascular Disease Area Coordinator, IR-Hospital of Sant Pau, Barcelona, Spain
  • Birgit Beger, CEO, European Heart Network
  • Prof Knut Borch-Johnsen, Medical Advisor, World Diabetes Foundation
  • Dr Ratna Devi, Chair of ISPOR Patient Council; CEO DakshamA Health and Education; Past Chair of IAPO
  • Alan Donnelly, Convenor of The G20 Health and Development Partnership; Executive Chairman, Sovereign Sustainability and Development
  • Prof Damien Gruson, Head of Department of Laboratory Medicine, Cliniques Universitaires Saint Luc, Brussels, Belgium; Chair, Emerging Technology Division, International Federation of Clinical Chemistry and Laboratory Medicine
  • Prof Richard Hobbs, Chair, European Primary Care Cardiovascular Society; President, International Primary Care Cardiovascular Society; Professor of Primary Care, University of Oxford, UK
  • James Kennedy, Director of Public Affairs, European Society of Cardiology
  • Lena Lymperopoulou, Executive Director, TA Policy Cardiovascular, Novartis; Representative, European Federation of Pharmaceutical Industries and Associations, Cardiovascular Health Platform
  • Alexander Olbrecht, Director Digital Health, MedTech Europe
  • Prof Fausto Pinto, Immediate Past President, World Heart Federation; Professor of Cardiology, University of Lisbon; Head of Cardiology Department & Heart and Vascular Department, Santa Maria University Hospital, Lisbon, Portugal
  • Prof Laurence Sperling, Professor in Preventive Cardiology, Emory University School of Medicine; Professor of Global Health, Rollins School of Public Health, Atlanta, US
  • Prof Izabella Uchmanowicz, Professor, Wroclaw Medical University, Wroclaw, Poland; President, ESC’s Association of Cardiovascular Nursing & Allied Professions
  • Prof James Ware, Professor of Cardiovascular and Genomic Medicine, Imperial College London, UK; Visiting Scientist at the Broad Institute of MIT & Harvard, US
  • Prof David Wood, Emeritus Professor of Cardiology, Imperial College London, UK & University of Galway, Ireland
  • AADIC Associação de Apoio aos Doentes com Insuficiência Cardíaca, Portugal
  • AEPOVAC Asociación Española de Portadores de Válvulas Cardíacas, Anticoagulados y Adultos con Cardiopatias Congénitas, Spain
  • AICARM Associazione Italiana Cardiomiopatie, Italy
  • Alliance du Coeur, France
  • Asia-Pacific Cardiovascular Disease Alliance
  • Association Vie Et Coeur (AVEC), France
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • British Society for Heart Failure, UK
  • Cardioalianza, Spain
  • Cardiomyopathy UK
  • CHEER Hearts – Connecting Hearts to End Heartbreak
  • Cliniques Universitaires Saint Luc
  • Croí, Ireland
  • Cuore Nostro, Italy
  • Dakshayani and Amaravati Health and Education, India
  • DCM Foundation, US
  • EchoMed, UK
  • Edwards Lifesciences
  • Emory University School of Medicine, US
  • European Atherosclerosis Society
  • European Federation of Pharmaceutical Industries and Associations
  • European Heart Network
  • European Primary Care Cardiovascular Society
  • European Society of Cardiology
  • FH Europe Foundation
  • FOKUS Patient, Sweden
  • G20 & G7 Health and Development Partnership
  • Heart Failure Patient Foundation, US
  • Heart Failure Warriors Northern Ireland, UK
  • Heart of a Giant Foundation, US
  • Heart Sistas, US
  • Heart Support Australia
  • Heart Valve Voice Canada
  • Heart Valve Voice Japan
  • Heart Valve Voice UK
  • Heart Valve Voice US
  • Heartlife Foundation of Canada
  • hearts4heart, Australia
  • Her Heart, Australia
  • Imperial College London, UK
  • Indian Alliance of Patient Groups
  • Initiative Herzklappe, Germany
  • Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, Spain
  • Instituto Lado A Lado Pela Vida, Brazil
  • International Primary Care Cardiovascular Societies
  • International Society for Pharmacoeconomics and Outcomes Research, Inc
  • Irish Pharmacy Union
  • Israeli Heart Association, Israel
  • Lithuanian Heart Failure Association
  • MedTech Europe
  • Meine Herzklappe, Austria
  • Mended Hearts, US
  • Mended Hearts Europe
  • Monash University, Australia
  • National Institute for Prevention and Cardiovascular Health, Ireland
  • NHS Foundation, UK
  • Novo Nordisk
  • PACO, Mexico
  • Panhellenic Heart Disease Association, Greece
  • ParSirdi.lv, Latvia
  • Plataforma Pacientes Fundación Española del Corazón, Spain
  • Roche
  • Royal Brompton Hospital, London
  • Salvando Latidos, Mexico
  • SAMS Asociacion, Spain
  • Serce na Banacha, Poland
  • Servier
  • SQ Develle Enterprises LLC, US
  • Stichting VrouwenHart, The Netherlands
  • University Mercatorum, Rome, Italy
  • University of California, San Francisco, US
  • University of Galway, Ireland
  • University of Oxford, UK
  • WomenHeart, US
  • World Diabetes Foundation
  • World Heart Federation
  • In addition, several individual patient advocates attended the 2023 Annual Global Heart Hub Unite Summit and contributed to the manifesto.

Tackling CVD requires a cohesive, global approach.

Join us in our ambition to achieve the implementation of these eight manifesto actions to make early detection and diagnosis of CVD a reality for all.

Global Heart Hub was pleased to work with The Health Policy Partnership as our knowledge partner on this initiative.

Global Heart Hub

This manifesto was an initiative by Global Heart Hub with the support of unrestricted grants from AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Edwards Lifesciences, Novo Nordisk, Roche and Servier. 

This first-of-its-kind manifesto represents the main output from Global Heart Hub’s 3rd Annual Unite Summit, held in Barcelona
on 8-9 November 2023. 

Global Heart Hub

Sign Up for Updates

Follow Us

Contact Us

Copyright 2024 Global Heart Hub | All Rights Reserved